Pfizer CEO says he’s planning for vaccine-resistant Covid strain, is confident company can react within months
CEO says vaccine-resistant variant less likely to arise if more people get vaccinated now
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Pfizer's CEO Albert Bourla said the company believes that it could be ready to counter a vaccine-resistant variant of Covid-19 within three months, should one arise.
The CEO made the statement on Tuesday during a Fox News segment.
“Every time that the variant appears in the world, our scientists are getting their hands around it,” Mr Bourla said during the segment. “They are researching to see if this variant can escape the protection of our vaccine. We haven’t identified any yet but we believe that it is likely that one day, one of them will emerge.”
The company spokesman said he anticipates a vaccine-resistant variant, but stressed that if more Americans take the shot, the chances of such a mutation occurring will decrease.
Around 52 per cent of Americans are currently fully vaccinated, according to the CDC, and approximately 61 per cent have taken at least one dose of the vaccine.
The Pfizer shot was given full approval by the US Food and Drug Administration on Monday, ending a much-repeated complaint among anti-vaxxers that the shots had not been fully approved.
The approval of the Pfizer shot also paves the way for employers and businesses to enact vaccine mandates for employees and customers.
During an appearance on the TODAY Show, Dr Anthony Fauci, the director of the National Institute of Allergy and Infectious Disease, said that a survey suggested that 30 per cent of those hesitant to take the vaccine would consider taking the shot now that it has been given full approval.
He also noted that mandates were more likely to occur with full approval in place.
“The second element is … that there will now be much more enthusiasm in mandating vaccines, be they in corporations and places of employment, universities, colleges, the military – all of that I believe will contribute greatly to the number of people vaccinated,” he said.
Full approval also allows Pfizer to advertise its vaccine.
However, Pfizer's CEO said the company's focus now was not convincing the unvaccinated to change their minds, but to increase the vaccine supply to help meet global demand.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments